As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year.
Kamada announced that on August 15, 2018, the Company, the Employees’ Committee of Kamada’s Beit Kama production facility in Israel (the “Employee’s Committee”), the Histadrut – General Federation of Labor in Israel (the “Histadrut”), and a Mediator appointed by the parties (the “Mediator”), signed a binding Memorandum of Understanding (the “Binding MoU”) that terminates the previously disclosed labor strike.
Kamada announced financial results for the three and six months
ended June 30, 2018.
Kamada announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the development plan for its proposed pivotal Phase 3 study for its proprietary Inhaled Alpha-1 Antitrypsin therapy (Inhaled AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD).
Since 1967, the lives of countless babies have been saved by the pioneering Rh Program – and to date, millions of doses of anti-D have been given to Rh negative women.
The results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA).
Kamada today announced financial results for the three months ended
March 31, 2018.
KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches.
Kamada announced that the company recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the proposed pivotal Phase 3 protocol for its proprietary Inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017.